\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe FFplus project has opened its second FFplus Open Call for Business Experiments. This call provides an opportunity for SMEs and startups across Europe —with no prior experience in high-performance computing (HPC) — to explore how these technologies can benefit and advance their own business development, with funding of up to €200,000 per project available. All submissions must be made by 26 August 2025 (17:00 Brussels time).
Who can apply?
Opportunities for companies active in generative AI?
Eligible costs:
Full details can be found in the call document.
For more info or support please visit www.enccb.be/FFPLUS-2025.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Digital, Industry & Space Climate, Energy, Mobility AI Continent
The Horizon Europe project AI-BOOST has launched 4 specific Generative AI challenges to drive significant research progress in different areas: Challenge 1: GenAI-Based Natural Language Mission Generator for Autonomous Robots in Agriculture (deadline: 25 August 2026) Challenge 2: Agentic AI for Automated CAD Generation and Autonomous Simulation... read more
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
